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Abstract 
Addiction to psychoactive substances is a debilitating condition underpinned by the interplay 
of genetic and environmental factors. At present, a key challenge for research is to delineate 
how, at a molecular level, these influences become ‘biologically embedded’, contributing to 
the onset and persistence of addictive behaviours. Recently, epigenetic processes that regulate 
gene expression have emerged as a potential mechanism of interest. In this commentary, we 
discuss the relevance of epigenetics to addiction research, starting with the current state of 
knowledge, what challenges we have yet to overcome, and what the future may hold in terms 
of research methodology and translational potential.  
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What we have learned so far 
The ‘epigenome’ refers to a collection of processes that influence when and where genes are 
expressed, without changing the DNA sequence itself. One of these processes, DNA 
methylation (DNAm), has received much attention. DNAm refers to the addition of a methyl 
group to DNA base pairs – primarily the cytosine base in C-G dinucleotides – which has been 
observed to repress transcription, resulting in decreased gene expression (Jones, 2012). 
Studies have found that DNAm: (i) is influenced by genetic architecture (e.g. cis-SNP effects; 
McRae et al., 2014); (ii) is sensitive to pre- and postnatal environmental exposures (e.g. 
nutrition, toxins, stress; Kofink et al., 2013); (iii) plays an essential role in normative 
development (e.g. cellular differentiation, ageing; Smith and Meissner, 2013); and (iv) 
disrupted patterns are associated with altered biological processes and the emergence of 
disease states (Klengel et al., 2014). Consequently, interest in the potential role of DNAm in 
addiction is fast increasing.   
 Much of what we currently know about DNAm and addiction has come from animal 
studies, which enable the experimental manipulation of important factors such as the type, 
extent and timing of substance exposure. These have begun to shed light into the complex, 
reciprocal and developmentally-moderated relationship between substance use/exposure, 
DNAm and addiction. For example, exposure to substances (as early as preconception) has 
been shown to alter DNAm patterns in the brain (e.g. Govorko et al., 2012). In turn, these can 
mediate gene activation in regions involved in reward processing(e.g. hypothalamus) and 
memory consolidation (e.g. hippocampus), driving long-term neuroadaptations that underlie 
the onset and persistence of addiction (Gangisetty et al., 2014; Nestler, 2014). Animal studies 
have also provided some tentative evidence for intergenerational transmission of DNAm 
patterns implicated in addiction risk (e.g. Finegersh and Homanics, 2014) as well as 
normalization of drug-induced DNAm changes by chemical intervention (e.g. Bekdash et al., 
2013). In humans, studies have also supported a link between DNAm and addiction, reporting 
methylomic differences (e.g. in neurotransmitter genes) between substance users and drug-
free controls across a number of tissue types and substances (Cecil et al., 2015; Harlaar and 
Hutchison, 2013).  
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What our biggest challenges are and how they may be addressed 
Despite these promising findings, research on DNAm and addiction currently faces a number 
of challenges that limit the conclusions that can be drawn. 
 
1. Limited knowledge of the epigenome 
Commonly used platforms only capture a small percentage of the methylome (e.g. Illumina 
450k, <2%) and typically focus on CpG-rich ‘islands’ near promoter regions – as such many 
regions of potential relevance to addiction remain largely inaccessible (Non and Thayer, 
2015). To complicate matters (and in contrast to the genome), DNAm has been shown to vary 
over time and across multiple factors, including age, tissue and cell-type (Liang and Cookson, 
2014). This is especially relevant for addiction – a brain-based disorder, which in human 
epigenetic studies is either examined in vivo via peripheral tissues (e.g. blood, saliva) or in 
post-mortem neural tissue, making it difficult to infer epigenetic changes in live brain tissue. 
 The way forward. Rapid technological advances, such as the development of whole-
genome bisulfite sequencing (WGBS), will make it increasingly possible to obtain a more 
complete picture of DNAm, covering regions relevant to addiction in greater depth. 
Moreover, the compilation of reference datasets will be crucial for establishing a ‘normative’ 
benchmark of DNAm, against which to compare addiction-related epigenetic findings 
(Shakya et al., 2012). In particular, sampling of multiple tissues over time will make it 
possible to quantify peripheral-CNS-tissue variability (e.g. Walton et al., 2015) and to 
establish why certain substance-induced DNAm signatures remain stable while others change 
over time. Strategies for big data integration will also help to establish the functional 
significance of addiction-related DNAm changes at different biological levels (e.g 
transcriptomic, metabolomic, neural; Gomez-Cabrero et al., 2014).  
 
2. Issues with research methodology 
DNAm data is multifactorial, high-dimensional and inter-correlated, raising questions about 
how best it should be analysed (Almouzni et al., 2014). So far, studies on DNAm and 
addiction have varied widely in methodology (e.g. genomic coverage, quality control, sample 
size, covariates, analysis, significance threshold) as well as the choice of phenotype (e.g. type 
of substance, severity of use, clinical features, diagnostic criteria), limiting comparability of 
findings. Notably, addiction studies using candidate gene vs hypothesis-free, epigenome-wide 
analyses have generally produced inconsistent results (Cecil, et al., 2015).  
Epigenetics of Addiction 
5 
 
 The way forward. Guidelines for best practice are continuously being fine-tuned, and 
the increased availability of standardized pipelines will help maximise convergence across 
studies (Morris and Beck, 2015). Furthermore, the development of data reduction strategies 
that draw on the interrelatedness of DNAm data (e.g. network/regional analyses) will help 
alleviate the burden of multiple testing and move beyond single-site analyses (Rotival and 
Petretto, 2014; Hass et al., 2015). Replication of findings (e.g. via independent 
samples/techniques) will also become increasingly important in weeding out false-positives, 
as was the case for genetic studies. The availability of methylomic data in relation to different 
drug classes will make it possible to distinguish substance-specific markers from markers that 
are ‘shared’ across multiple substances, which may reflect a general liability to addiction. 
Future work will also be needed to establish how methylomic signatures may vary depending 
on the phenotype of interest (e.g. chronic vs acute substance exposure; substance use vs abuse 
vs addiction).  
 
3. Difficulties in establishing causal pathways 
Most studies on DNAm and addiction have employed a cross-sectional, case-control design. 
This is problematic because, unlike the genome, DNAm is sensitive to both genetic and 
environmental factors, raising issues of reverse causation. In other words, it is difficult to 
establish whether identified DNAm differences are a predisposing factor for addiction and/or 
a consequence of long-term substance use. Even when studies have been prospective, DNAm 
has typically been examined at a single time point, precluding the possibility of examining 
how substance exposure and DNAm interrelate over time to influence addiction risk.  
 The way forward. Causal inference may be strengthened by capitalising on cross-
species designs, using findings from experimental/mechanistic animal models to inform the 
investigation of DNAm markers in humans. Studies will also need to better quantify the 
relative contribution of genetic and environmental factors on DNAm (e.g. via twin, GCTA 
and GxE analyses; Klengel and Binder, 2015; Trzaskowski and Plomin, 2015) and employ 
prospective designs to examine whether DNAm patterns predict substance use liability, as 
well as addiction risk. Specifically, this will require the use of longitudinal designs that make 
it possible to compare pre- vs post-exposure methylomic signatures during adolescence, a key 
period of vulnerability for the development of substance use disorders (Crews et al., 2007). 
Collecting repeated-measures data on substance exposure, DNAm and addiction status will 
also enable to test mediation hypotheses (e.g. via structural equation modelling; Cecil et al., 
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2014), while the use of advanced inference methods (e.g. Two-Step Mendelian 
randomization; Relton and Davey Smith, 2012) will make it possible to use genetic 
instruments in order to examine causal pathways.   
 
What the future might hold: Implications and translational potential 
Epigenetics has been heralded as a key ‘missing link’ in the aetiology of complex disorders, 
including addiction. However, as we gain an appreciation of the challenges facing epigenetic 
research, we must be mindful to manage expectations. Bearing this in mind, there are a 
number of ways in which epigenetic research may in future contribute to our understanding, 
prevention and treatment of addiction.  In the first place, findings may refine existing models 
of how risk factors for addiction become biologically embedded. Longitudinal modelling of 
environmental and epigenetic data may also be used to pinpoint specific windows of 
biological vulnerability (e.g. prenatal period, adolescence) that may benefit most from 
preventive action. On the longer term, epigenetic variation in specific genes may be used as 
biomarkers for substance exposure, addiction risk, and response to treatment. Chemical 
normalization of aberrant DNAm patterns examined in animal studies may also be extended 
to humans. Ultimately, this knowledge may inform the development of novel strategies for 
treating addiction, paving the way for personalised intervention.  
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